Urgent Warning: Nearly 2 Billion Lives at Risk from Metabolic Liver Disease by 2050, Study Reveals
A study published in the Lancet Gastroenterology & Hepatology projects that metabolic liver disease-specifically metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)—will impact approximately 1.8 billion people worldwide by 2050. This alarming rise is largely attributed to increasing obesity rates and elevated blood sugar levels.
Currently, around 1.3 billion individuals live with MASLD, reflecting a staggering 143% increase over the past 30 years. The recent figures indicate that approximately one in six people (16%) are affected, underscoring the urgency of addressing this global health crisis. The study, conducted by the Institute for Health Metrics and Evaluation at the University of Washington, illustrates the rapid growth of this liver condition, which affected about 500 million people in 1990.
By 2023, the prevalence had surged to 1.3 billion, and the global rate is anticipated to climb to 1.8 billion by 2050-a 42% increase from current estimates. The incidence rate now stands at 14,429 cases per 100,000 people, up 29% since 1990. Notably, MASLD shows higher prevalence rates among men and peaks in older adults aged 80-84. However, the majority of cases are found in younger demographics, with men aged 35-39 and women aged 55-59 being particularly affected.
Key drivers of MASLD complications include high blood sugar, elevated body mass index (BMI), and smoking, establishing a strong correlation with type 2 diabetes and obesity. Certain regions, particularly North Africa and the Middle East, exhibit disproportionately high rates of MASLD, but many countries worldwide are experiencing sharp increases. In the UK, for instance, the prevalence rose by 33% between 1990 and 2023, marking the largest increase in Western Europe. Australia and the United States saw increases of 30% and 22%, respectively.
Despite the rising number of MASLD cases, the overall health impact-measured in years lost due to illness or death-has remained stable. This suggests that advancements in treatment and healthcare have enabled individuals with the disease to lead longer, healthier lives, with many cases occurring in the early stages of the disease. Nevertheless, the uptick in cases signifies that numerous individuals remain at risk for severe complications such as liver cirrhosis or cancer.
MASLD often correlates with excess weight and can typically be managed through lifestyle changes. Often asymptomatic, many individuals are unaware they have the condition until they undergo tests for other reasons. Symptoms, when they do occur, may include fatigue, malaise, and pain or discomfort in the liver region.
The study’s authors stress the importance of recognizing MASLD as a pressing global health issue, particularly as it increasingly affects younger adults. They call for heightened awareness, policy development, and intervention strategies to mitigate the condition’s growing impact and prevent future complications.
As this liver disease trend continues to rise, it is imperative for public health officials, healthcare providers, and individuals to prioritize prevention and management strategies to address this urgent health crisis effectively.
Tags: MASLD, metabolic liver disease, global health, obesity, diabetes, public health.
Original Source: https://www.theguardian.com/society/2026/apr/13/almost-2bn-to-be-affected-by-metabolic-liver-disease-by-2050-study-suggests
Category :
Tags:
Publish Date: 2026-04-14 04:00:00
